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Edited by Sandro SonninoAbstract Demyelination, the proteolytic degradation of the ma-
jor membrane protein in central nervous system, myelin, is in-
volved in many neurodegenerative diseases. In the present
in vitro study the proteolytic actions of calpain, human trypsin
1 and human trypsin 4 were compared on lipid bound and free
human myelin basic proteins as substrates. The fragments
formed were identiﬁed by using N-terminal amino acid sequenc-
ing and mass spectrometry. The analysis of the degradation
products showed that of these three proteases human trypsin 4
cleaved myelin basic protein most speciﬁcally. It selectively
cleaves the Arg79-Thr80 and Arg97-Thr98 peptide bonds in
the lipid bound form of human myelin basic protein. Based on
this information we synthesized peptide IVTPRTPPPSQ that
corresponds to sequence region 93–103 of myelin basic protein
and contains one of its two trypsin 4 cleavage sites, Arg97-
Thr98. Studies on the hydrolysis of this synthetic peptide by
trypsin 4 have conﬁrmed that the Arg97-Thr98 peptide bond is
highly susceptible to trypsin 4. What may lend biological interest
to this ﬁnding is that the major autoantibodies found in patients
with multiple sclerosis recognize sequence 85–96 of the protein.
Our results suggest that human trypsin 4 may be one of the
candidate proteases involved in the pathomechanism of multiple
sclerosis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Multiple sclerosis (MS), an inﬂammatory disease of the hu-
man central nervous system, is associated with demyelinationAbbreviations: B, bound; Cbz, carbobenzyloxy; Chaps, 3-[(3-cholam-
idopropyl)dimethylammonio]-1-propanesulfonate; ESI-MS, electro-
spray ionization mass spectrometry; F, free; HPLC,
high-performance liquid chromatography; LB, lipid bound; LF, lipid
free; MBP, myelin basic protein; MS, multiple sclerosis; pNA, para-
nitroanilide; SDS–PAGE, sodium dodecyl sulfate polyacrilamide gel
electrophoresis; Tris–HCl, a,a,a-Tris-(hydroxymethyl)-methylamine
hydrochloride
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doi:10.1016/j.febslet.2005.12.067(for reviews see Refs. [1–6]). Although autoreactive CD4+ T
cells are considered central to initiate inﬂammation, analysis
of tissue lesions indicates the contribution of myelin basic pro-
tein (MBP) and myelin oligodendrocyte glycoprotein speciﬁc
CD8+ T cells and antibodies as well [6]. Because myelin pro-
teins are targets of proteolysis in MS, several brain proteases
that degrade these proteins in vitro or in vivo, like matrix
metalloproteinase-9 [7], calpain [8], myelencephalon-speciﬁc
protease (MSP) [9] and plasminogen activators [10], have been
implicated in myelinolysis. To this list now we add a new pro-
tease, human trypsin 4 that due to its immunohistochemical
localization in the brain and to its substrate speciﬁcity [11] ap-
pears to be a further candidate to process the immunodomi-
nant MBP fragments in MS.
Human trypsinogen 1 and 2 genes (PRSS1 and PRSS2,
respectively) are located on chromosome 7, whereas the gene
(PRSS3) encoding mesotrypsinogen and human trypsinogen
4 is located on chromosome 9 [12]. Mesotrypsin or human
brain trypsin (human trypsin 4) is a unique isoform of trypsin
in which an arginine replaces the conserved glycine at position
193. This explains both the enhanced substrate restriction and
enhanced inhibitor resistance of the protease [13,14]. Human
trypsinogen 4 mRNA was the only typical trypsin-related
mRNA found in the brain [15].
In the present study we have compared the proteolytic ac-
tion of human trypsin 4 on human MBP in both lipid free
(LF) and lipid bound (LB) forms with those of human trypsin
1 and calpain. The generated fragments and cleavage sites were
identiﬁed by using N-terminal amino acid sequencing and elec-
trospray ionization mass spectrometry (ESI-MS) analysis. The
results have demonstrated that human MBP is a good sub-
strate for human trypsin 4 and that human trypsin 4 selectively
cleaves peptide bonds Arg79-Thr80 and Arg97-Thr98 of LB
MBP. Thus it processes a fragment that, in line with some pre-
vious and recent proposals [1,4,5], may contain immunodomi-
nant epitopes for CD4+ and CD8+ myelin reactive T cell clones
from MS patients.2. Materials and methods
2.1. Isolation of MBP
Myelin basic protein was puriﬁed from a 10.4 g sample of human
occipital cortex white matter. Human brain samples were obtained
from Prof. Miklo´s Palkovits (Laboratory of Neuromorphology,blished by Elsevier B.V. All rights reserved.
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stored at 80 C until use. LF MBP extraction procedure was per-
formed by the chloroform method of Maatta et al. [16]. The total
yield of LF MBP was 11.6 mg as determinated by the bicinchoninic
acid method (Sigma) according to the manufacturer’s instruction.
The LF MBP isoforms were separated on a high-performance liquid
chromatography (HPLC) column (Aquapore OD-300 220 · 4.6 mm,
Perkin–Elmer) by elution of a gradient of acetonitrile from 30% to
60% in 0.1% triﬂuoroacetic acid. The purity of the separated LF
MBP isoforms was tested by sodium dodecyl sulfate polyacrilamide
gel electrophoresis (SDS–PAGE). The identiﬁcation was performed
by ESI-MS. MBP was also puriﬁed in lipid bound form by using
a procedure based on 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (Chaps) solubilization according to Riccio et al.
[17].2.2. Digestion of MBP with human trypsin 4, human trypsin 1 and
m-calpain
The enzyme:substrate molar ratios of 1:70 000, 1:10 000 and 1:50
for human trypsin 1, human trypsin 4 and m-calpain, respectively,
were chosen to result in similar extents of digestion of human
MBP. Recombinant human trypsins 1 and 4 were prepared as descri-
bed previously [18], and m-calpain was obtained from Dr. Pe´ter
Tompa, Institute of Enzymology, Budapest. Buﬀers contained
20 mM, pH 7.5, a,a,a-Tris-(hydroxymethyl)-methylamine hydrochlo-
ride (Tris–HCl) and 10 mM CaCl2 for all digestions and additional
5 mM 2-mercaptoethanol for the calpain digestion. The digestions
were carried out at room temperature and aliquots were taken at
5, 15, 30 and 60 min. The resulting proteolytic fragments were sepa-
rated by SDS–PAGE (17%), electroblotted onto ProBlot polyvinyli-
dene diﬂuoride membranes (PE Biosystems) and then subjected to
N-terminal amino acid sequencing by a Procise sequencer (ABI
494, Applied Biosystems). The 1 hour aliquots of the human trypsin
4 and m-calpain digests were also analyzed by a Hewlett Packard
HPLC-MS/ESI system.Fig. 1. SDS–PAGE of LF human myelin basic protein isoforms (lane 1
(Fermentase), b-galactosidase 116 kDa, bovine serum albumin 66.2 kDa, oval
Bsp98I 25 kDa, b-lactoglobulin 18.4 kDa, lysozyme 14.4 kDa.) (A). HPLC ch
the 17.2 kDa LF MBP isoform and peak 2 the 18.5 kDa LF MBP isoform (B
masses of 18.52 and 17.25 kDa, respectively (C).2.3. Solid-phase peptide synthesis
Oligopeptides (MBP-fragments IVTPRTPPPSQ and IVTPR-Phos-
pho-T-PPPSQ and internal standard HAAPPSADIQIDI) were synthe-
sized by an ABI 431A Automated Peptide Synthesizer with Fmoc
chemistry. All chemicals used were of analytical or sequencing grade.
HPLC-grade acetonitrile was obtained from Romil (Great Britain).
N,N-diisopropylethylamine, triﬂuoroacetic acid and all chemicals for
the peptide synthesis and sequencing were obtained from ABI-
Perkin–Elmer (USA).
2.4. Enzymatic digestion of synthesized oligopeptides
56 lMof both synthetic MBP fragments was digested with 0.009 lM
human trypsin 4 and human trypsin 1, while the concentration of m-
calpain was 1.9 lM. Composition of the reaction buﬀers were
0.05 M Tris–HCl of pH 8.0 and 0.02 M CaCl2 for human trypsins
and 0.02 M Tris–HCl, pH 7.5, 0.01 M CaCl2 and 0.005 M b-mercap-
toethanol for the human m-calpain digestion. Activites of human tryp-
sins 4 and 1 were the same on the Cbz-Ala-Ala-Pro-Arg-pNA substrate
(Sigma). Three independent digestions were carried out with 5 ll of en-
zymes in 150 ll reaction volume at 25 C. The digestions were termi-
nated at 0, 10, 30 and 60 min by transferring 30 ll aliquots to the
injector tubes containing 10 ll of 5 M acetic acid. The aliquots were
analyzed by an automated HPLC system.
2.5. RP-HPLC analysis
A PE-ABI automated HPLC instrument with a 140 CMicrogradient
System, a Series 200 Autosampler, a 785 A Programmable Absorbance
Detector, and a 900 Series Interface equipped with an Aquapore OD
300 reversed phase column (2.1 · 220 mm, Perkin–Elmer) was used
for the separations. 15 ll aliquots of the terminated digestion mixtures
were loaded onto the column. Chromatographic runs were carried out
with the general conditions as follows: 300 ll/min ﬂow rate; eluent A
was water containing 0.1% (v/v) triﬂuoroacetic acid; eluent B was
80% acetonitrile and 20% water containing 0.1% (v/v) triﬂuoroacetic
acid. A 10 min equilibration followed by a 0–35% B linear gradient
was applied at 220 nm detection wavelength. Chromatographic data: myelin basic proteins; lane 2: protein molecular weight markers
bumin 45 kDa, lactate dehydrogenase 35 kDa, restriction endonuclease
romatography of human myelin basic protein isoforms. Peak 1 contains
). Mass spectrogram of myelin basic protein isoforms, with molecular
P. Medveczky et al. / FEBS Letters 580 (2006) 545–552 547obtained by RP-HPLC were collected and quantitated by the Perkin–
Elmer Turbochrom 4 chromatography software.3. Results
3.1. Isolation and identiﬁcation of MBP
LF and LB human myelin basic proteins were puriﬁed from
occipital cortex white matter with the chloroform [16] andFig. 2. As followed by SDS–PAGE, the time-course of the digestion of L
enzyme:substrate ratios (mol:mol) were 1:70 000, 1:10 000 and 1:50, respec
marked with arabic numbers on the gels (A). The fragments isolated from th
shown and the identiﬁed cleavage sites in the structure of LF MBP3 (see TaChaps extraction methods [17], respectively. Two bands were
identiﬁed in the LF MBP by SDS–PAGE (Fig. 1A). After
HPLC separation of the two proteins (Fig. 1B) their molecular
masses were determined by ESI-MS analysis (Fig. 1C) and
found to be 17.25 (Peak 1) and 18.52 kDa (Peak 2), respec-
tively. These correspond to the two major human myelin basic
protein isoforms, MBP4 (isoform 6) and MBP3 (isoform 5)
(Fig. 1C).F MBP3 by human trypsin 1, human trypsin 4 and m-calpain. The
tively. The bands corresponding to the newly formed fragments are
e m-calpain and human trypsin 4 digests with their molecular masses
ble 1) are demonstrated in (B).
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and m-calpain
Fig. 2A shows the time-course of degradation of human LF
MBP3 with three diﬀerent proteases. Human trypsin 1 was
used as a reference protease in order to compare its speciﬁcity
to that of human trypsin 4. During the incubation period dis-
tinct patterns of fragments emerged. Keeping the diﬀerent pro-
tease to substrate ratios in mind (see Section 2), it appears that
human trypsin 1 hydrolyzes MBP3 much less selectively than
human trypsin 4 and m-calpain. Cleavage patterns by the latter
two proteases, however, signiﬁcantly diﬀer from each other. It
is interesting to note that a similar extent of digestion of hu-
man MBP3 by human trypsin 4 requires about 200 times less
human trypsin 4 than m-calpain (Fig. 2A). Identiﬁcation of
the LF MBP fragments generated by m-calpain (fragmentsTable 1
LF MBP fragments obtained by human trypsin 4 and m-calpain digestions
Bands in the m-calpain digest Fragment Molecular mass (D
HGFLP 15692
1 N-terminusb 7706
(HGFLP) NDc 8010
TPPPSQ 7699
HGFLPR 4366
2a SDYKS (4197) NDd
2 TPPPSQ 3541
TAHYGS 3694
3 SLPQK 3130
N-terminusb 2828
aSecond fragment in the same band.
bBlocked (acetyled) N-terminus, not detectable by amino acid sequencing.
cNot detected by sequencing.
dNot detected by MS.
Table 2
Comparison of fragments obtained by digestion with human trypsin 4 of LF
Bands from the LB MBP
digest with human t4
Fragment Molecular mass
HGFLP 15692
A N-terminusc 10821e
Aa TQDEN 9823e
Ab N-terminusc 8697e
(HGFLP) NDd 8010
TPPPSQ 7699
HGFLPR 4366
B GLSLSR 6693e
TAHYGS 3694
C TQDEN 2141e
Ca TPPPSQ 1024e
N-terminusc 2828
aSecond fragment in the same band.
bThird fragment in the same band.
cBlocked (acetyled) N-terminus, not detectable by sequencing.
dNot identiﬁed by sequencing.
eNot determined by MS.1–3 in Table 1 and Fig. 2B) and human trypsin 4 (fragments
4–8 in Table 1 and Fig. 2B) was performed by N-terminal ami-
no acid sequencing and mass spectrometry of the electroblot-
ted fragments. According to this analysis calpain cleaves
peptide bonds Gly70-Ser71, Arg97-Thr98, Ala131-Ser132 gen-
erating fragments 1–70 (fragment 1), 71–97 (fragment 3), 98–
131 (fragment 2) and 132–170 (fragment 2\) with molecular
masses of 7706, 3130, 3541 and 4200 Da (the last value was
estimated by SDS–PAGE only). By using the same strategy
the following peptide bonds were located as human trypsin 4
cleavage sites for LF MBP: Arg25-His26, Arg65-Thr66 and
Arg97-Thr98 (Table 1 and Fig. 2B). Human trypsin 4 and
m-calpain have one common cleavage site, peptide bond
Arg97-Thr98 that is, in fact, the major cleavage site for both
human trypsin 4 and m-calpain. The digestions by humana) Amino acid positions Bands in the human t4 digest
26– 4
1–70
26–97 5
98– 5a
26–65 6
132–
98–131
66–97 7
71–97
1–25 8
and LB MBP
(Da) Amino acid positions Bands from LF MBP
digest with human t4
26– 4
1–97
80–
1–79
26–97 5
98– 5a
26–65 6
108–
66–97 7
80–97
98–107
1–25 8
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2, Fig. 3A and B). Fragments originating from the Arg25-
His26 and Arg65-Thr66 peptide bond cleavages (see LF
MBP processing) could not be detected in the LB MBP digest.
Instead, the Arg79-Thr80 and Arg107-Gly108 cleavage sites
are unique to LB MBP. These are close in the amino acid se-
quence to peptide bond Arg97-Thr98 that in the case of LB
MBP also appears to be the most susceptible cleavage site
for trypsin 4.
3.3. Digestion of synthetic MBP fragments by human trypsin 4,
human trypsin 1 and calpain
As Fig. 4 shows, hydrolysis of human MBP fragment
IVTPRTPPPSQ by the same amounts of human trypsins 4
and 1 result in comparable extents of cleavage: 65% and 77%
of the peptide remained intact, respectively. With this experi-
ment for the ﬁrst time we demonstrated a higher hydrolytic
activity of human trypsin 4 than trypsin 1 on a peptide sub-
strate. In contrast, m-calpain did not attack this fragment at
all (Fig. 4). As data in Table 3 show, the Thr98-phosphory-
lated fragment of MBP, IVTPR-Phospho-T-PPPSQ resists
all proteases tested.4. Discussion
Several lines of evidence support that T cell responses to cer-
tain proteins of the protective myelin sheath around neuronal
axons play an important role in the pathomechanism of MS.
Though debated by some authors [2,3,6], increased levels and
characteristic speciﬁcitiy proﬁles of anti-MBP response in the
cerebrospinal ﬂuid and brain of patients with MS have also
been reported [1,4,5]. The myelin sheath may by demaged byFig. 3. Comparison by SDS–PAGE of the LF and LB MBP digestion by hu
fragments formed from LF and LB MBP, respectively (A). (B) The proteolyti
4 cleavage sites in the structure of MBP.several mechanisms such as digestion of surface myelin by pro-
teases in macrophages and glial cells, by cytokine-mediated
injuries or even via direct attacks by CD8+ T cells, by antibod-
ies and complement [6]. Diﬀerent proteolytic enzymes have
been implicated in myelinolysis [7–10]. In an in vitro study,
here we have shown that the proteolytic processing of LB
MBP by recombinant human trypsin 4 generates an MBP frag-
ment, residues 80–97 (Table 2, Fig. 3), that comprises the
structure of a putative immunodominant T cell epitope of
MBP, residues 85–96 [1,4–6]. We have also shown that human
trypsin 4 digests MBP more eﬃciently than calpain (Fig. 2),
another protease implicated in the pathomechanism of MS
[8]. Our preliminary studies on the localization of trypsinogen
4- and trypsin 4-like immunoreactivities in glial cells of human
spinal cord and brain [11] lend further support to the possibil-
ity that trypsin 4 may function as a myelin processing protease
of microglia and oligodendroglia.
Recently, a signiﬁcantly increased CD8+ T cell response has
been described to MBP peptides containing residues 87–95 and
111–119 [4]. Based on this ﬁnding the possibility should also be
considered that trypsin 4 may be involved the generation of a
cytotoxic T cell response attacking oligodendrocytes that
express both MHC class I molecules and MBP.
From chemical point of view human MBP is a 170-amino
acid protein, containing 19 arginyl and 12 lysyl residues which
account for its basic character. MBP strongly interacts with
the lipids in the multilamellar myelin sheath that surrounds
the axons. Though the exact secondary and tertiary structures
of MBP within the myelin sheath have not been elucidated yet,
a common feature of the proposed structural models is that the
immunodominant epitope center of the protein, or at least a
part of it, is located at the cytoplasmic surface of oligodendro-
cytes [1,19,20]. This suggestion is in line with our resultsman trypsin 4. Arabic numbers and capital letters refer the proteolytic
c fragments from LB MBP with their molecular masses and the trypsin
Fig. 4. Hydrolysis of the non-phosphorylated synthetic MBP fragment IVTPRTPPPSQ by calpain, human trypsin 4 (t4) and human trypsin 1 (t1) as
followed by RP-HPLC. ‘0’ is the untreated MBP peptide.
Table 3
The percentage of residual peak area of the undigested synthetic MBP fragments in the diﬀerent digests
Trypsin 1 Trypsin 4 Calpain
IVTPRTPPPSQ 77.25 65.08 100
IVTPR-Phospho-T-PPPSQ 100 100 100
With the same amount of proteases IVTPRTPPPSQ digestion was carried out for 10 min and IVTPR-Phospho-T-PPPSQ digestion for 60 min.
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LB MBP are preferentially cleaved by the proteases examined
(Figs. 2 and 3). The protective eﬀect of lipids against proteol-
ysis is clearly illustrated by the diﬀerence of cleavage patterns
of LF and LB MBPs (Fig. 3). It may follow from these consid-
erations that the antibody response in MS is directed either to
this exposed region of intact LB MBP, or to the processed epi-
tope. Another consequence of the unique structural feature of
this region, residues 93–103, is that some of its residues are
subject to post-translational modiﬁcations, like phosphoryla-
tion of Thr98 by a mitogen-activated protein kinase [21].
Post-translational modiﬁcations of MBP are thought to play
a key role in the demyelinating process [22]. In this context it
is interesting to note that in our model experiments with syn-
thetic peptides trypsin 4 cleaved the Arg97-Thr98 bond in
MBP fragment IVTPRTPPPSQ (residues 93–103) more eﬃ-
ciently than human trypsin 1 (Fig. 4 and Table 3). The phos-
phorylation of Thr98 to yield peptide IVTPR-phospho-T-
PPPSQ, however, rendered peptide bond Arg-phospho-Thr,
residues 97–98, in the peptide resistant toward all three prote-
ases tested (Table 3).
Concerning the biological function of trypsin 4 in human
brain only two possibilities have been reported so far. In astro-
cytes of transgenic mice expressing human trypsinogen 4 en-
hanced GFAP expression and an increase in the amount of
amyloid fragments were found [23]. A recent study on human
cell lines suggests that human trypsin 4 might function as an
agonist of protease-activated receptors, PAR 2 and 4 [24]. As
a further possibility, our present study suggests that human
trypsin 4 may be one of the proteases involved in the patho-
mechanism of multiple sclerosis. This proposal, together with
our preliminary data on the detection and immunohistochem-
ical localization of the active enzyme in some glial cells of hu-
man brain [11], is based on the present in vitro experiments
that demonstrate eﬃcient and speciﬁc actions of trypsin 4 on
LF and LB MBP and small synthetic peptides containing a
physiologically (or pathologically) crucial processing site in
MBP [21,22].
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